Allakos Announces a Restructuring to Focus on Development of AK006

January 17, 2024

https://www.globenewswire.com/news-release/2024/01/16/2809723/0/en/Allakos-Announces-a-Restructuring-to-Focus-on-Development-of-AK006.html

SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) — Allakos Inc. (the Company) (Nasdaq:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced a restructuring to reduce costs and to focus on AK006 clinical development and additional preclinical programs. As a result, the Company’s cash runway is expected to extend into mid-2026.

Read more at globenewswire.com

Related news for (ALLK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.